NEA 16 GP, LLC has an estimated net worth of $278 Million. This is based on reported shares across multiple companies, which include Marker Therapeutics, Inc., Mirum Pharmaceuticals, Inc., GENOCEA BIOSCIENCES, INC., Metacrine, Inc., Trevi Therapeutics, Inc., Akouos, Inc., Black Diamond Therapeutics, Inc., Arsanis, Inc., Regulus Therapeutics Inc., and NeueHealth, Inc..

2019 was NEA 16 GP, LLC's most active year for acquiring shares with 13 total transactions. NEA 16 GP, LLC's most active month to acquire stocks was the month of September. 2020 was NEA 16 GP, LLC's most active year for disposing of shares, totalling 7 transactions. NEA 16 GP, LLC's most active month to dispose stocks was the month of May. 2019 saw NEA 16 GP, LLC paying a total of $58,338,581.88 for 38,924,291 shares, this is the most they've acquired in one year. In 2022 NEA 16 GP, LLC cashed out on 14,671,143 shares for a total of $750,662.12, their largest year based on trade value.